Approved and available therapies include TTR stabilizers such as tafamidis and acoramidis (indicated for ATTR amyloidosis with cardiomyopathy) [21,22], as well as gene-silencing therapeutics that reduce expression of serum TTR by either RNAi (patisiran (indicated for polyneuropathy) and vutrisiran (indicated for polyneuropathy and cardiomyopathy)) [12,23–25] or antisense oligonucleotide-based mechanisms (inotersen and eplontersen (indicated for polyneuropathy)) [26]. The gene discussed is TTR; the disease is cardiomyopathy.